Trial Profile
Risk factors for serious adverse events associated with abatacept versus conventional synthetic DMARDs in patients with rheumatoid arthritis: A retrospective nested case-control study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2018
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 14 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism